Oct. 5, 2020, 4:09 p.m.
London: Even as the coronavirus pandemic creates havoc all around the world, there is a ray of hope on the horizon for the countless people at risk from the COVID-19 virus.
A team of scientists at the Oxford University has achieved big success in their efforts to produce a coronavirus vaccine that will be able to contain the spread of the COVID-19 virus.
Scientists at the Oxford University had achieved limited success in the human trials of the coronavirus vaccine. Although the human trials were stopped after some volunteers developed problems, the scientists at Oxford University are confident of achieving success in the near future.
According to reports, if all goes well, the COVID-19 vaccine being developed by the Oxford University will be available to the general public, within the next 3 months.
Scientists at the Oxford University have informed that the Covid-19 vaccine can be introduced in the UK within the next three months. Trials for the coronavirus vaccine are currently in an advanced stage. Scientists doing research on the coronavirus vaccine at the Oxford University expect it to be approved by regulators by the end of this year. If the process goes according to schedule, every adult in the UK will get a dose of this coronavirus vaccine within six months.
The Oxford University said that during the human trials it was found that this coronavirus vaccine developed immunity in people to fight the COVID-19 virus. A total of 1,077 people were part of this coronavirus vaccine trial.
Evidence has been found that the people who were vaccinated during the human trials developed coronavirus fighting white blood cells and antibodies. It is considered a major achievement in the worldwide in coronavirus vaccine manufacturing against the COVID-19 pandemic.
Amidst all this, the European Medicine Agency (EMA) has started reviewing the vaccines of AstraZeneca and Oxford University. The European Medicine Agency (EMA) has said that it has begun reviewing data for a possible COVID-19 vaccine from AstraZeneca and Oxford University.